Donald R Mattison

Safety and effectiveness of NMDA receptor antagonists for depression: A multidisciplinary review.

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy July 2022 Thomas J Moore, Abdallah Alami, G Caleb Alexander et al.

Ketamine, an anesthetic available since 1970, and esketamine, its newer S-enantiomer, provide a novel approach for the treatment of depression and other psychiatric disorders. At subanesthetic doses, the two drugs, along with their older congener, phencyclidine (PCP), induce a transient, altered mental state by blocking the N-methyl-D-aspartate (NMDA) receptor for glutamate, the primary...